Lupus profundus
ICD-10 L93.2 · ICD-11 EB51.Y.3

Systemic Treatment of Lupus Profundus

This protocol provides structured, evidence-based treatment guidance for Lupus profundus. It covers agent selection and combination strategy for patients requiring systemic therapy.

Treatment approach: The protocol involves systemic agents, used preferably in combination with antimalarials. The complete agent selection criteria, sequencing, and full treatment algorithm are available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

  1. We recommend MTX up to 20 mg per week as a second-line treatment, primarily in SCLE patients, preferably subcutaneously and in addition to antimalarials.
  2. We recommend retinoids as second-line systemic treatment in selected CLE patients unresponsive to other treatments, preferably in addition to antimalarials.
  3. In CLE, the recommended dose for acitretin and isotretinoin is 0.2 to 1.0 mg/kg body weight/day.
  4. We recommend dapsone as second-line treatment in refractory CLE, preferably in addition to antimalarials.
  5. We recommend to start dapsone with a low dose treatment (50 mg/day) and to increase it to a maximum of 1.5 mg/kg according to clinical response and side-effects.
View source ↗